Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02164721 · ClinicalTrials.gov registry record · NA
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
A NA study, sponsored by University of Rochester.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT02164721 is a NA study that has completed, run by University of Rochester. The registered enrollment target is 30 participants.
The verdict
NCT02164721, a NA study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial or study is to determine if cardiac resynchronization therapy (CRT) can be a benefit to people who have impaired heart function due to past treatment with chemotherapy and/or chest radiation. The investigators are looking to enroll approximately 30 eligible subjects with heart failure in this trial. All patients enrolled and registered in the study will be implanted with a cardiac resynchronization therapy device that includes an implantable cardiac defibrillator (CRT-D). Clinical histories, physical exams, and external device testing will be collected both at the time of enrollment in the trial and during follow-up study visits. Following implantation of the CRT-D, patients will be contacted by phone at 3 months and will have a scheduled clinic visit follow-up at 6 months.
Interventions
- DEVICE Three-lead CRT-D (Defibrillator)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-02-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02164721
The ClinicalTrials.gov registry entry for NCT02164721 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Three-lead CRT-D (Defibrillator) is the first listed.
NCT02164721 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02164721 about?
NCT02164721 is a clinical study titled "Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy". The purpose of this trial or study is to determine if cardiac resynchronization therapy (CRT) can be a benefit to people who have impaired heart function due to past treatment with chemotherapy and/or chest radiation. The investigators are looking to enroll approximately 30 eligible subjects with he...
What is the current status of trial NCT02164721?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-11. Estimated completion is 2019-02-06.
What interventions are being tested in trial NCT02164721?
The interventions under investigation include: Three-lead CRT-D (Defibrillator) (DEVICE).
Who is sponsoring clinical trial NCT02164721?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.